newsfilter
← Latest News
GlobeNewswire·

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon